Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
Get the inside scoop on how colleges assess your high school and its course rigor. Featuring a former Admissions Officer, you'll gain crucial insights and actionable strategies during this 60-min ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results